Skip to main content

Autolus Therapeutics plc

AUTL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001730463

In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.

Members of Congress who traded AUTL

No member of Congress has reported a trade in Autolus Therapeutics plc since 2020.

Source: U.S. House Clerk and Senate Office of Public Records (eFD). Amounts are the ranges filers report.